{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-26-000005","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2026-01-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.465172+00:00","generated_at":"2026-05-16T09:20:46.733660+00:00","sec_items":["3.02","5.02","5.07","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AEON shareholders approve PIPE/Daewoong exchange; BPD Type 2a meeting held with FDA","bullets":["Shareholders approved PIPE financing, Daewoong note exchange, and 2023 incentive plan at special meeting; exchange closed Jan 21.","Daewoong exchanged $15M senior secured notes for 11.9M shares, 11.2M pre-funded warrants, $1.5M new note, and 8M warrants.","Second closing of PIPE expected week of Jan 26: 4.6M shares, 6.6M warrants, and up to 6.6M true-up warrants.","AEON held BPD Type 2a meeting with FDA for ABP-450 biosimilar; awaiting official minutes within ~30 days.","Fifth amendment to license agreement with Daewoong adjusts termination purchase right based on Daewoong's sale of 50% of its shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-26-000005","json":"https://secwatch.observer/filing/0001837607-26-000005.json","markdown":"https://secwatch.observer/filing/0001837607-26-000005.md","text":"https://secwatch.observer/filing/0001837607-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000005/0001837607-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000005/aeon-20260121x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:20:46.733660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}